Regulation of the human vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites.
1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the active form of Vitamin D, mediates gene transcription through the Vitamin D receptor (VDR), a nuclear receptor expressed in multiple normal and transformed cell types. In mammary epithelial cells, including those derived from breast cancers, 1,25(OH)(2)D(3) induces growth arrest and/or apoptosis through VDR dependent mechanisms, and VDR agonists represent potential therapeutic agents for hyperproliferative diseases, including cancer. Since target cell sensitivity to 1,25(OH)(2)D(3) and its analogs reflects VDR expression, understanding the transcriptional regulation of the VDR gene is fundamental to development of VDR agonists as therapeutic agents. The studies reported here focused on molecular characterization of the promoter region upstream of exon 1c in the human VDR gene. In transient transfection assays, luciferase reporter constructs containing -800 to +31 of the VDR gene exhibit basal promoter activity in T47D breast cancer cells which is enhanced by 1,25(OH)(2)D(3), estrogen and the phytoestrogen resveratrol. Deletion constructs and site-directed mutagenesis were used to map three distinct GC-rich Sp1 consensus sites that independently mediate the effects of estrogen, resveratrol, and 1,25(OH)(2)D(3) on VDR promoter activity. Up-regulation of the VDR promoter by 1,25(OH)(2)D(3) was mapped to an Sp1 site 261bp upstream of exon 1c, estrogen responsiveness to a proximal Sp1 site beginning at -50, and resveratrol regulation to a distal Sp1 site beginning at -381. Studies with estrogen receptor (ER) subtype specific ligands suggest that the effect of estrogen on VDR promoter is dependent on both ERalpha and ERbeta, whereas the effect of resveratrol is dependent only on ERalpha. In summary, these studies demonstrate transcriptional regulation of the exon 1c VDR promoter in breast cancer cells, and identify three distinct GC-rich, Sp1 consensus sites that differentially confer responsiveness to estrogen, resveratrol and 1,25(OH)(2)D(3).
Wietzke
Jennifer A
JA
Department of Biological Sciences, University of Notre Dame, 214 Galvin Life Science Building, Notre Dame, IN 46556, USA.
Ward
Erin C
EC
Schneider
John
J
Welsh
JoEllen
J
D001665:Binding Sites; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D016384:Consensus Sequence; D018899:CpG Islands / Q000235:genetics; D004958:Estradiol / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000187:drug effects / Q000502:physiology; D047629:Estrogen Receptor beta / Q000187:drug effects / Q000502:physiology; D005091:Exons / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D018167:Receptors, Calcitriol / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D000077185:Resveratrol; D016329:Sp1 Transcription Factor / Q000378:metabolism*; D013267:Stilbenes / Q000494:pharmacology; D015533:Transcriptional Activation; D014407:Tumor Cells, Cultured; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D018167:Receptors, Calcitriol; D016329:Sp1 Transcription Factor; D013267:Stilbenes; C118756:dihydroxy-vitamin D3; D014807:Vitamin D; D004958:Estradiol; D000077185:Resveratrol